197 related articles for article (PubMed ID: 12748346)
1. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study.
Helldén A; Odar-Cederlöf I; Diener P; Barkholt L; Medin C; Svensson JO; Säwe J; Ståhle L
Nephrol Dial Transplant; 2003 Jun; 18(6):1135-41. PubMed ID: 12748346
[TBL] [Abstract][Full Text] [Related]
2. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
[TBL] [Abstract][Full Text] [Related]
3. Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis.
Berry L; Venkatesan P
J Clin Virol; 2014 Dec; 61(4):608-10. PubMed ID: 25440915
[TBL] [Abstract][Full Text] [Related]
4. An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study.
Lindström J; Helldén A; Lycke J; Grahn A; Studahl M
J Antimicrob Chemother; 2019 Dec; 74(12):3565-3572. PubMed ID: 31504577
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
[TBL] [Abstract][Full Text] [Related]
6. Differential diagnosis of central nervous system involvement in a patient treated with acyclovir.
von Euler M; Axelsson G; Helldén A
Ther Drug Monit; 2013 Aug; 35(4):417-9. PubMed ID: 23851913
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous analysis of acyclovir and its metabolite using hydrophilic interaction liquid chromatography-tandem mass spectrometry.
Takeda S; Ueno S; Zenda R; Muto K; Iseki K; Harada K
J Anal Toxicol; 2024 May; 48(4):204-209. PubMed ID: 38441245
[TBL] [Abstract][Full Text] [Related]
8. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient.
Yang HH; Hsiao YP; Shih HC; Yang JH
Int J Dermatol; 2007 Aug; 46(8):883-4. PubMed ID: 17651180
[TBL] [Abstract][Full Text] [Related]
9. Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid.
Darville JM; Lovering AM; MacGowan AP
Int J Antimicrob Agents; 2007 Jul; 30(1):30-3. PubMed ID: 17428641
[TBL] [Abstract][Full Text] [Related]
10. A decreasing plasma concentration of a toxicologically active metabolite 9-carboxymethoxymethylguanine after dialysis - A potential new clinical biomarker for improving encephalopathy in patients treated with acyclovir.
Unita R; Adachi K; Inada A; Shimizu M; Beppu S; Yamazaki H
J Infect Chemother; 2023 Nov; 29(11):1068-1070. PubMed ID: 37437659
[TBL] [Abstract][Full Text] [Related]
11. Acute kidney injury and acyclovir-associated encephalopathy after administration of valacyclovir in an elderly person with normal renal function: A case report and literature review.
Kenzaka T; Sugimoto K; Goda K; Akita H
Medicine (Baltimore); 2021 May; 100(21):e26147. PubMed ID: 34032768
[TBL] [Abstract][Full Text] [Related]
12. Acyclovir kinetics in end-stage renal disease.
Laskin OL; Longstreth JA; Whelton A; Rocco L; Lietman PS; Krasny HC; Keeney RE
Clin Pharmacol Ther; 1982 May; 31(5):594-601. PubMed ID: 7075109
[TBL] [Abstract][Full Text] [Related]
13. More about acyclovir neurotoxicity in patients on haemodialysis.
Gómez Campderá FJ; Verde E; Vozmediano MC; Valderrábano F
Nephron; 1998; 78(2):228-9. PubMed ID: 9496746
[No Abstract] [Full Text] [Related]
14. Valacyclovir neurotoxicity: clinical experience and review of the literature.
Asahi T; Tsutsui M; Wakasugi M; Tange D; Takahashi C; Tokui K; Okazawa S; Okudera H
Eur J Neurol; 2009 Apr; 16(4):457-60. PubMed ID: 19187258
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir neurotoxicity can be effectively managed by hemodialysis.
Kambhampati G; Pakkivenkata U; Kazory A
Eur J Neurol; 2011 Mar; 18(3):e33. PubMed ID: 21087359
[No Abstract] [Full Text] [Related]
16. [Acyclovir encephalopathy in a peritoneal dialysis patient despite adjusting the dose of oral acyclovir: a case report].
Kawabe Matsukawa M; Suzuki Y; Ikuma D; Suwabe T; Uesaka Y; Sugimoto I
Rinsho Shinkeigaku; 2019 Dec; 59(12):834-839. PubMed ID: 31761838
[TBL] [Abstract][Full Text] [Related]
17. Aciclovir and valaciclovir neurotoxicity in patients with renal failure.
Almond MK
Nephrol Dial Transplant; 2003 Dec; 18(12):2680; author reply 2680-1. PubMed ID: 14605302
[No Abstract] [Full Text] [Related]
18. Aciclovir-induced neurotoxicity.
Vonberg FW; Dawson A; Scott G; Davies N
Pract Neurol; 2023 Apr; 23(2):157-159. PubMed ID: 36601749
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity associated with acyclovir in end stage renal failure.
Kitching AR; Fagg D; Hay NM; Hatfield PJ; Macdonald A
N Z Med J; 1997 May; 110(1043):167-9. PubMed ID: 9196501
[TBL] [Abstract][Full Text] [Related]
20. [On the mailing list: use of acyclovir in patients on hemodialysis].
D'Amico M; Fraticelli M; Limido A
G Ital Nefrol; 2005; 22(1):66-9. PubMed ID: 15786379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
